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Background: Newborn screening (NBS) for cystic fibrosis (CF) has become standard practice in many countries. Consequently, the prevalence of
infants with intermediate sweat test results has increased. This study examined clinical practices in the United States (US) related to intermediate
sweat test results subsequent to NBS.
Methods: Respondents from 77 (47% response rate) US CF centers completed telephone surveys documenting clinical practices related to
intermediate sweat chloride levels (30–59 mmol/L) following abnormal NBS.
Results: Thirty percent of centers followed CF Foundation guidelines for classifying intermediate results. There was much variability in sweat
testing procedures, diagnostic labels, additional diagnostics, addressing prognosis, and services offered to parents. CF center staff identified a need
for resources to better address the uncertainty associated with intermediate results.
Conclusion: Results suggest the need for education regarding current guidelines and consensus regarding the nomenclature and services offered to
families of newborns with intermediate sweat test results.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Newborn screening; Intermediate sweat test; Genetic counseling; Uncertainty1. Introduction
1.1. Newborn screening and diagnosis of cystic fibrosis
Newborn screening (NBS) programs test neonates for treatable
genetic and metabolic disorders to prevent or minimize
complications. NBS for cystic fibrosis (CF) has been implemen-
ted in Australia, Europe, New Zealand, North America, andmany
Latin American countries [1–3]. Following an abnormal NBS
result for CF, infants require sweat testing to diagnose or rule out
CF [4,5]. In the United States (US), sweat chloride analysis using
pilocarpine iontophoresis is typically conducted at accredited or☆ Institute where work was conducted: University ofWisconsin,Madison,WI.
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doi:10.1016/j.jcf.2011.07.002affiliate pediatric CF Centers [5]. According to recommendations
from the US Cystic Fibrosis Foundation (CFF) and the European
Cystic Fibrosis Society (ECFS), sweat chloride results for
infants≤6 months of age are classified as normal (chloride
levels≤29 mmol/L), abnormal (chloride levels≥60 mmol/L), or
intermediate, the term used byCFF or equivocal, the term used by
ECFS (chloride levels 30–59 mmol/L) [4,1,6]. Hereafter, “inter-
mediate” is used throughout this report because this study was
conducted in the US. If results fall within the intermediate
diagnosis range, the CFF recommends a repeat sweat test within
2 months [4]. Additional testing may include comprehensive
Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
analysis, fecal elastase evaluation, and pulmonary cultures [7].
1.2. Intermediate results
The intermediate classification is a relatively new category
arising largely from the inclusion of genetic testing in NBS.d by Elsevier B.V. All rights reserved.
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sweat test results [8] and uncertainty about the severity and
onset of CF symptoms. This uncertainty creates challenges for
clinicians in communicating results to parents [4] and leads to
concerns for parents about the health status of their infants
[9]. Parent anxiety is fueled by the association of CF with a
shortened lifespan. Although practice guidelines offer direction
for clinical management of infants with intermediate results [7],
there is no internationally accepted protocol that addresses
psychosocial aspects of intermediate results. This study docu-
mented current practices associated with intermediate CF results
including sweat testing procedures, diagnostic labels, parame-
ters used to classify intermediate results, additional diagnostic
tests prescribed, how providers address prognosis, and services
offered to parents.
2. Methods
2.1. Design
This descriptive study used a telephone survey to investi-
gate how CF center care providers in the US address inter-
mediate sweat test results following abnormal NBS for CF.
The Health Sciences Institutional Review Board at University
of Wisconsin-Madison approved this study.
2.2. Recruitment
Using telephone contact information obtained from the
Cystic Fibrosis Foundation, we recruited participants from all
164 pediatric CF care centers in the US between 11/23/2009
and 3/4/2010. A decision tree facilitated the identification of
individuals who self-identified “as the most likely person to
have information about how intermediate results are handled” at
their center in the context of NBS. A script guided verbal
consent procedures which involved a description of the study,
measures to protect participant confidentiality, and the volun-
tary nature of participation. Potential participants were also
informed that they did not have to answer any question they
were not comfortable with answering or if they did not know the
answers. When initial attempts to reach the appropriate staff
person were unsuccessful, we made 1–3 additional attempts.
2.3. Sample
The final sample included 77 (47%) of the 164 accredited and
affiliate pediatric CF care facilities. Respondents represented
56 accredited and 21 affiliate pediatric CF centers in 38 states.
Participant job titles included nurses (n=33), clinic coordinators
(n=24), CF center directors (n=17), genetic counselors (n=14),
physicians (n=4), social workers (n=2), respiratory therapists
(n=2), pulmonary diagnosticians (n=2), nutritionist (n=1), and
pediatric pulmonary clinic director (n=1). Several participants
reported more than one title. Most respondents were highly
experienced in CF care (M=15.7±9.98 years of experience,
range=2–43 years). The mean length of time that NBS for
CF had been mandated in participants' states was 4.4 years(SD=4.8). The mean number of intermediate sweat tests in the
last 12 months was 7.1.2.4. Data collection
The telephone survey was developed by a team of content
and methodology experts. Four board-certified CF center ge-
netic counselors reviewed the survey for appropriateness of
content and ease of administration. After incorporating their
feedback, the final 48-item questionnaire incorporated two
clinical scenarios, 41 close-ended questions, and 7 open-ended
questions. Content included respondent demographic informa-
tion, state NBS protocols, clinic procedures, and follow-up
services/referrals offered to parents of infants with intermediate
results. Interviews were scheduled at the convenience of the
participant and lasted about 20 min. Responses were entered
into a password protected Excel file for coding and analysis.
To ensure confidentiality, each participating CF center was as-
signed a six-digit code.3. Analysis and results
Closed-ended questions were coded, responses summarized,
and percentages calculated. We conducted a directed and
summative content analysis using procedures described by
Krippendorff [10] for open-ended questions. Resulting codes
were based on consensus ratings of major themes derived from
the data.3.1. Representativeness of sample
We obtained data from the CFF regarding the number of
patients receiving services at each CF center from 2006 to 2008.
We compared the mean patient volume of our sample (M=84.9)
to the mean of the non-participating centers (M=80.2). Results
of the t-test showed no significant difference (t-test value=
−0.477 and p=0.63). Most participants reported NBS algo-
rithms that involve some combination of measuring immuno-
reactive trypsinogen (IRT) followed by DNA testing: 67% IRT/
DNA, 14% IRT/IRT, 10% IRT/DNA/gene sequencing, 3%
IRT/DNA+IRT, 5% no response, and 1% other.3.2. Sweat testing procedures
Most respondents (84%) reported bilateral collection of
sweat. Ninety percent reported using the pilocarpine iontopho-
resis method; 10% gave no response. Fifty-eight percent
reported that parents were informed about the possibility of
intermediate results before sweat testing, 22% said their center
did not inform parents of this possibility, 10% only informed
parents sometimes, and 10% did not respond. Seventy-one
percent of centers informed parents of the sweat test results the
same day as testing. The remaining 29% did not indicate when
they informed parents about sweat test results.
Table 1
Follow-up procedures for intermediate sweat test results.
Scenario Response
Yes No None
N (%) N (%) N (%)
First scenario
Repeat sweat test 56 (73%) 13 (17%) 8 (10%)
Clinical work-up 24 (31%) 45 (58%) 8 (10%)
Gene sequencing 23 (30%) 46 (60%) 8 (10%)
Other 12 (16%) 56 (73%) 9 (12%)
Larger mutation panel 10 (13%) 59 (77%) 8 (10%)
Second scenario
Repeat sweat test 46 (60%) 19 (25%) 12 (16%)
Clinical work-up 35 (46%) 30 (39%) 12 (16%)
Other 10 (13%) 54 (70%) 13 (17%)
Gene sequencing 5 (7%) 60 (78%) 12 (16%)
Larger mutation panel 2 (3%) 63 (82%) 12 (16%)
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Seventy-five percent of CF centers offered genetic coun-
seling to parents either all or most of the time. These centers
also described a high uptake rate by parents (74%). Providers
of genetic counseling services included genetic counselors
(79%), CF center physicians (27%), nurses (6%), and CF center
directors or coordinators (2%). The timing of genetic counseling
varied: after results were known (52%), during sweat collection
(17%), after sweat testing was completed, but before results
were known (16%), before sweat testing was conducted (13%),
and whenever the family wished to receive counseling (4%).
More than one response was accepted.
3.4. Parameters for intermediate classification
The lower limit for an intermediate classification was most
commonly reported as 30 mmol/L (71%) or 40 mmol/L (17%).
The remaining respondents reported lower limits of 0 mmol/L
(1%), 20 mmol/L (3%), 25 mmol/L (3%), 31 mmol/L (1%), or
35 mmol/L (1%). The “0 mmol/L” response was associated
with a NBS protocol requiring two mutations for a sweat test
referral. Three percent did not respond. Most centers (53%)
used 60 mmol/L as the upper limit of the intermediate range.
Other upper limits included 59 mmol/L (32%), 40 mmol/L
(5%), 30 mmol/L (3%), 29 mmol/L (1%), and 25 mmol/L (1%).
Five percent did not respond.
Using a logistic regression model, we analyzed the data to
determine whether length of experience with NBS or size of CF
center (number of patients/year) was associated with responses
that are consistent with CFF guidelines for the upper (59 mmol/
L) and lower limits (30 mmol/L) for intermediate status. We
also performed these analyses two ways: using models that
corrected for providers' years of experience as a CF specialist
and using models that did not correct for this variable. None of
the results was statistically significant. Thus, the lack of
knowledge did not appear to be a function of experience with
NBS, size of the center, or years of provider experience.
There was a wide range of definitions for the intermediate
sweat test result with some reporting the use of more than one.
The most commonly reported terms used to present interme-
diate test results to the families included “CFTR-related
metabolic syndrome” (CRMS; 57%), “atypical CF” (40%),
and “non-classic CF” (12%). Other labels (34%) were “CFTR-
related abnormality”, “abnormal sweat chloride level”, “some
CFTR dysfunction”, “variant CF”, “abnormal NBS with two
CFTR mutations”, “borderline”, “elevated IRT”, and “CF-like”.
Eight percent did not use a label until a definite diagnosis was
determined but we did not explore how long infants remained
undiagnosed.
3.5. Follow-up assessment
We created two clinical scenarios to offer participants
opportunities to illustrate how they would approach follow-up
assessment and care for newborns with intermediate test results.
The first scenario involved a Caucasian one month-old infantwith an elevated IRT and a single F508del mutation. The
second scenario was similar, but NBS results detected two
mutations, F508del and R117H-7T. Each scenario was
modified to indicate that the infant's sweat test results fell
within the intermediate range used by the respondent's center.
As noted in Table 1, the most common response (73%) to the
first scenario was to repeat the sweat test, but not to proceed
with genetic testing using a larger mutation panel or gene
sequencing, nor to have the child evaluated in the CF clinic.
Time frame for repeating the sweat test included infant age of
2 months (44%); infant age of 3–6 months (17%), and within a
month of original sweat test (12%). Other centers individualized
the follow-up testing, e.g., repeating the sweat test when the
infant's weight reached 8–10 lb or when insurance approval
was obtained.
For the second scenario, most respondents (60%) reported
that they would repeat the sweat test either at 2 months of age
(34%) or 3–6 months of age (25%). Centers were much less
likely to proceed with additional genetic analysis using a larger
mutation panel or gene sequencing. Centers were divided about
whether the child should be evaluated in the CF clinic.
The R117H-7T gene variant was considered to be a symptom-
causing mutation by 12% of respondents and not symptom-
causing by another 12%. Most centers (55%) said that the allele
is “sometimes” considered a symptom-causing mutation. Twenty
one percent did not respond.
3.6. Prognosis
We asked providers to describe how they would address
the infant's prognosis with parents in each scenario. A content
analysis of provider responses revealed five content areas:
(a) uncertainty of clinical implications, (b) hopeful prognosis,
(c) chronic nature of the condition, (d) no discussion of prognosis,
and (e) CFF guidelines for care. Respondents who offered parents
a hopeful prognosis included some combination of the following
five points: (a) infant would be healthy, (b) infant is probably
just a CF carrier, (c) CF is a spectrum disorder, (d) advances in
Table 2
Factors associated with prognosis presentation to parents.
Factors Response
Yes No None
N (%) N (%) N (%)
CFTR mutations 58 (75%) 16 (21%) 3 (4%)
Health of newborn 53 (69%) 21 (27%) 3 (4%)
Symptoms present 60 (78%) 14 (18%) 3 (4%)
Parental anxiety 35 (45%) 39 (51%) 3 (4%)
Parental knowledge 56 (73%) 18 (23%) 3 (4%)
Other 20 (26%) 54 (70%) 3 (4%)
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people with CF continues to increase. Fig. 1 shows the attention
given to each content area based on the scenario. Providers who
offered a hopeful prognosis for the second scenario emphasized
the same points, except for the probability that the child was just a
carrier.
Factors influencing the prognosis conversation included
infant genotype and health, as well as parental anxiety and
knowledge. Other variables involved the timing of the
discussion, family history of CF, parents' stress level, parents'
social support, parents' state of denial, sweat chloride levels,
previous clinical experiences with particular mutations, infor-
mation parents reported reading, infant age, and provider's
expectations about parent adherence to follow-up recommen-
dations (Table 2). One respondent stated that all patients
received the same counseling regardless of other factors.
3.7. Additional resources
Respondents identified a need for additional resources to
more effectively address the needs of families whose infants had
intermediate sweat test results. Multiple responses were
accepted for needed resources including educational materials
(47%), clinical personnel (18%), parent-to-parent services (4%),
funding for more definitive testing (4%), and follow-up
telephone contact with parents and parent-to-parent support
(4%). Several respondents were uncertain about needing
additional resources (4%) or stated none were needed (9%)
and 10% did not respond.
3.8. Follow-up contact with families
Thirty-eight percent of respondents stated that they contacted
parents between initial intermediate results and follow-up
testing or clinical visits; 31% said they did not initiate contact
with parents; and 26% reported contacting parents only some
of the time and 5% did not respond. An average of 31% (range
0–100%) reported that parents called their centers with ques-Fig. 1. Major categorical themetions or concerns about their infant following intermediate
sweat test results.
3.9. Additional referrals and resources
Most respondents (75%) reported that they direct parents to
internet sites to answer questions, typically the CFF site, www.
cff.org. When asked if they had adequate resources for parents
dealing with the uncertainty of intermediate sweat tests,
respondents stated yes (35%), sometimes (34%), and no (28%).
4. Discussion
The results of this study illustrate the vast variability in US
clinical practices associated with intermediate sweat test results.
Only 30% of respondents report following CFF guidelines for
classifying sweat chloride results within the intermediate range.
When an infant's result falls within the intermediate classifica-
tion, follow-up evaluation and care can vary. Most centers repeat
the sweat test, but at varying ages. Consequently, infants with
the same sweat chloride levels receive different standards of care
across sites. There is also much variability in lexicons used to
describe the intermediate classification. This finding may reflect
the debate within the larger CF professional community about
terminology, e.g. CFF guidelines use the term, CFTR-related
metabolic syndrome while ECFS guidelines do not.s for discussing prognosis.
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participants did not have to answer any question they were not
comfortable with answering or to which they did not know
the answers, the “no responses”may reflect participants' lack of
knowledge or non-adherence to established guidelines. In either
case the high frequency of no responses in this survey suggests
knowledge deficits across multiple aspects of the intermediate
classification for sweat test results following abnormal NBS for
CF.
CFF and ECFS guidelines for infants with intermediate or
equivocal results were published in 2009 [7,6]. Our findings
might reflect the short period of time between the publication of
that article and the data collection for this study. Standardization
is crucial to provision of consistent and optimal clinical inter-
ventions, communication with parents and among colleagues,
as well as development of research protocols. Findings suggest
a need for center staff involved in NBS to again become familiar
with these guidelines, with particular emphasis on the inter-
mediate classification.
Results suggest a paucity in parent educational materials
and availability of specific resources for families with infants
who have intermediate results. Parent educational materials
describing the intermediate classification should be based on
empirical evidence, use consistent terms, be written at low
literacy, and available in multiple languages. Given the ever-
increasing complexity of the genetics of CF, especially for the
relatively new intermediate classification, it is essential that
genetic counseling services be incorporated into a comprehen-
sive approach to follow-up care.
Several CF centers offered parents opportunities to speak
with or read stories about other parents whose children had
intermediate results. Evidence suggests that such referrals could
alleviate parental anxiety and sense of isolation, while providing
a network of support [9]. While knowing that they are not alone
in their experience may be helpful to some parents, such
referrals should be used cautiously with the caveat that all
infants are unique and the experiences of a particular family
might not be the same for others.
About 51% of responses to our second scenario described
hopefulness as a central ingredient in counseling parents about
their infant's prognosis. Hope has been associated with
increased quality of life in patients with various medical
conditions [11]. Uncertainty can be framed as having the
potential for favorable outcomes. The challenge for providers is
striking a balance between hopeful optimism and the unknown
potential for symptom development.
About 38% of respondents reported that they initiated
contacts with families between the time of intermediate sweat
test results and follow-up clinical appointments. Such contacts
could help families cope with the uncertainty of intermediate
results by answering their questions and providing emotional
support. Hamilton and Grant [12] integrated telephone contacts
into a model of care for patients waiting for cancer treatment.
These phone contacts with patients reportedly offered anticipa-
tory guidance about clinical procedures, created an advocate
within the complex health care system, and reduced patient
anxiety. Incorporating this type of follow-up service mightaddress many of the psychosocial needs parents of infants with
intermediate results have identified thus far.
We acknowledge several limitations of the current study. We
relied on the initial contact person at each CF center to direct us
to the most appropriate staff member to complete the survey.
Perhaps the results would have been different if we had only
interviewed the CF center directors. That said, participants self-
identified as being knowledgeable about NBS procedures and
clinical practices related to intermediate results. Thus, results
suggest that they were not as knowledgeable as professed or the
centers did not adhere to CFF guidelines—both merit closer
examination and possible remediation. Although data collection
procedures were standardized and scripted, there could have
been subtle stylistic, gender, or age differences in the inter-
viewers that could have affected some participant responses.
Despite these limitations, this report, the first to systematically
document clinical practices regarding neonates with interme-
diate sweat results following abnormal NBS for CF, detected
evidence of many inconsistencies in practice.
5. Conclusion
With the international expansion of NBS to include CF,
the number of parents who will receive intermediate sweat test
results for their infant will increase. The results of this survey
suggest the need for staff education regarding established guide-
lines for the classification of intermediate sweat test results and
for consensus regarding the nomenclature and clinical follow-up
of infants with intermediate results and their families.
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